Peritraumatic dissociation consistently predicts posttraumatic stress disorder (PTSD). Avoidant coping may serve as a mechanism through which peritraumatic dissociation contributes to PTSD symptoms. Path analysis was used to examine whether avoidant coping assessed 6 weeks following a motor vehicle accident mediated the relationship between in-hospital… (More)
Avoidance coping (AVC) is common in individuals with posttraumatic stress disorder (PTSD) and in individuals with alcohol use disorder (AUD). Given that PTSD and AUD commonly co-occur, AVC may represent a risk factor for the development of comorbid posttraumatic stress and alcohol use. In this study, the relationship between AVC and PTSD symptoms (PTSS) was… (More)
OBJECTIVE We examined the prevalence of smoking behaviors and their association with specific psychiatric disorders in a representative sample of youth from behavioral health clinics in Puerto Rico. METHOD A complex sampling design was used to select the sample, and analyses were conducted to account for the unequal selection probability, stratification,… (More)
Emerging support for the roles of both early trauma and family environment in the development of dissociative symptomatology is complicated by the frequent co-occurrence of dysfunctional family environments and childhood maltreatment. The present investigation prospectively examined the influence of family environment on dissociative symptom course in 82… (More)
The empirical examination of personality characteristics related to the experience of strong negative emotions and the associated physiological response may help account for idiosyncratic responses to life events in schizophrenia. The current study examines the relationship between levels of neuroticism and arousability and physiological and emotional… (More)
The present study examined whether the use of albuterol within hours of a motor vehicle accident (MVA) impacted subsequent posttraumatic stress symptoms (PTSS). Participants receiving albuterol had less severe overall PTSS and hyperarousal symptoms at 6 weeks and less severe reexperiencing symptoms at 1 year post-MVA than those who did not receive albuterol.